Idorsia Pharmaceuticals Ltd. has reported the discovery of novel galectin-3 (Gal-3) inhibitors for the potential treatment of fibrotic and inflammatory diseases. Galactins are a family of glycan-binding proteins associated with various biological processes, including apoptosis, inflammation, fibrosis, angiogenesis, immunomodulation or tumor proliferation.